XERS analyst estimates
Xeris Biopharma (XERS) analyst ratings, the average price target and its range, and every firm's latest call.
XERS analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 6, 2026 | Barclays | Xeris Biopharma price target raised to $14 from $12 at Barclays | $14.00 |
| Sep 10, 2026 | Leerink Partners | Xeris Biopharma price target raised to $16 from $12 at Leerink | $16.00 |
| Aug 20, 2026 | Barclays | Xeris Biopharma price target raised to $12 from $9 at Barclays | $12.00 |
| Dec 8, 2025 | Barclays | Xeris Biopharma initiated with an Overweight at Barclays | $9.00 |
| Oct 29, 2025 | Oppenheimer | Xeris Biopharma price target raised to $18 from $8 at Oppenheimer | $18.00 |
| Mar 7, 2025 | Piper Sandler | Xeris Biopharma price target raised to $4 from $3 at Piper Sandler | $4.00 |
| Nov 11, 2024 | H.C. Wainwright | Xeris Pharmaceuticals (XERS) PT Raised to $6.60 at H.C. Wainwright | $6.60 |
| Oct 23, 2024 | Oppenheimer | Oppenheimer Reiterates Outperform Rating on Xeris Pharmaceuticals (XERS) | $5.00 |
| May 10, 2024 | Piper Sandler | Xeris Pharmaceuticals (XERS) PT Lowered to $3 at Piper Sandler | $3.00 |
| Apr 28, 2022 | Craig-Hallum | Craig-Hallum Initiates Coverage On Xeris Biopharma Holdings with Buy Rating, Announces Price Target of $6.5 | $6.50 |
- 3 firms rate XERS: 3 buy, 0 hold, 0 sell.
- The average price target is $15.00 from 2 analysts, from $14.00 to $16.00.
Updated 2026-11-03 00:44 UTC